Community code relating to medicinal products for human use, detailing requirements for MAAs, including documentation and data requirements.

Regulation (EU) 2019/6: Applies to veterinary medicines, ensuring regulatory compliance across EU veterinary sectors.

In addition, International Council for Harmonisation (ICH) guidelines, such as ICH E6 for Good Clinical Practice and ICH Q8-11 for pharmaceutical development, offer critical insights applied in the EU context.

Documentation Requirements

The documentation required for MAAs is extensive and encompasses various modules outlined in the Common Technical Document (CTD) format. Each module serves a specific purpose in demonstrating a product’s quality, safety, and efficacy.

Common Technical Document Modules

• Module 1: Administrative information and prescribing information relevant to EU regulations.
• Module 2: Summaries of clinical studies, non-clinical overview, and quality overall summarising data from modules 3 to 5.
• Module 3: Quality data covering drug substance (Chemistry, Manufacturing and Control – CMC) and drug product information.
• Module 4: Non-clinical study reports, including pharmacology and toxicology studies.
• Module 5: Clinical study reports presenting efficacy and safety evidence through clinical trial data.

Due diligence in assembling these documents is essential to meet agency expectations and mitigate regulatory risks.

Review/Approval Flow

The review and approval process for MAAs is complex and varies based on the type of application submitted. The primary pathways are the centralised procedure, decentralised procedure, mutal recognition procedure, and national procedure.

Centralised Procedure

The centralised procedure is obligatory for certain products, including those derived from biotechnology or intended for treating significant diseases such as AIDS, cancer, neurodegenerative disorders, and diabetes. The process involves:

• Submission of the MAA via the EMA’s eSubmission portal.
• Evaluation by the Committee for Medicinal Products for Human Use (CHMP).
• Issuance of an opinion and subsequent decision by the European Commission.

Decentralised Procedure (DCP)

The DCP involves simultaneous submission in multiple member states for products not authorised in any EU countries. The applicant can choose a reference member state (RMS) and subsequently receive approvals from concerned member states (CMS).

• The application process involves a detailed review by the RMS.
• Comments and questions raised during the consultation process need to be addressed effectively.

Mutual Recognition Procedure (MRP)

MRP permits an applicant to seek authorisation in additional member states for products that have already been authorised in one EU member state. It allows for a streamlined process by leveraging existing evaluations performed by the reference member state.

National Procedure

The national procedure is utilized for products intended for marketing authorisation in a single member state only. The application and review trajectory is primarily determined by the respective national competent authority (NCA).

Common Deficiencies

Typical deficiencies highlighted by regulatory agencies during MAA evaluations often stem from inadequate documentation, lack of clarity in justifications, and insufficient data. Understanding these deficiencies can guide regulatory affairs professionals in avoiding pitfalls.

Typical Agency Questions/Deficiencies

• Data Integrity: Ensure all submitted data are complete, consistent, and free from discrepancies.
• Justification of Variations: Clearly differentiate between variations and new applications. Variations should be justified based on significant changes in CMC or clinical data.
• Bridging Data: When presenting bridging studies, be prepared to explain how existing data supports the new application and ensure it is adequate to justify a regulatory approval route.

Avoiding Common Pitfalls

• Engage in early dialogue with regulatory bodies to clarify requirements and expectations.
• Conduct thorough internal reviews of submission documents and data prior to filing.
• Utilise external regulatory compliance firms for expert guidance and validation of dossiers.

Regulatory Affairs Decision Points

Regulatory affairs teams must consistently evaluate decision points that can significantly influence the filing process. Such decisions will ultimately impact the success of regulatory submissions.

When to File as a Variation vs. New Application

• Identify Changes: Determine if the changes to the product, such as adjustments in manufacturing sites, formulation changes, or new indications warrant a variation or necessitate a new application.
• Evaluation of Risk: Assess the potential impact of the change on the product’s quality, safety, and efficacy, to justify the choice of submission type.

Justifying Bridging Data

• Comprehensive Data Holes: Provide adequate evidence showing that the bridging study aligns with existing studies and supports proposed changes.
• Risk Assessment: Include a risk-benefit analysis that conveys confidence in the data to support regulatory requests.

Final Thoughts

The EU Marketing Authorisation Applications process demands rigorous planning, thorough documentation, and an in-depth understanding of regulatory expectations. For regulatory affairs, CMC, and labelling teams in US and EU pharmaceutical industries, mastering MAA strategies is essential for ensuring compliance and achieving prompt market access. Leveraging resources, interactions with regulatory bodies, and collaboration with external regulatory compliance firms can significantly enhance applicants’ chances of success.

For further information and guidance, stakeholders may refer to the official EMA website, where comprehensive resources on MAAs and regulatory requirements are available.